Loading

Samjin Pharmaceutical Co., Ltd.

June 16, 2025
Company Presentation
Immunology
Samjin Pharmaceutical Co., Ltd., a leading pharmaceutical company in Korea established in 1968, is dedicated to pioneering advancements in therapeutic innovation. Our portfolio features renowned products such as Platless® (antiarteriosclerotic agent), Neuracetam® (Nootropics), and Geworin® (NSAIDs), which have contributed significantly to our growth and success. At Samjin, we focus on developing innovative treatments for diseases with high unmet medical needs, particularly those that are difficult to treat and pose significant challenges to today’s society. Our research focuses on conditions such as various cancers, immune disorders, and obesity. We maintain a dynamic and diverse R&D pipeline, utilizing multiple modalities, including small molecules, ADCs, and TPDs. We actively collaborate with over 20 research institutions, and foster open innovation through strategic partnerships with domestic and global bio/pharmaceutical companies to drive medical breakthroughs.
Samjin Pharmaceutical Co., Ltd.
Company HQ City: Seoul
Company HQ State: Seoul
Company HQ Country: Korea, Republic of
Year Founded: 1968
Lead Product in Development: SJN314 (MRGPRX2 antagonist)

CEO

Yong Joo Choi

Year Founded

1968

Development Phase of Lead Product

Pre-Clinical

Exchange

17,500.00 ₩ (Feb 6)

Ticker

005500.KS (KOSPI)

When you expect your next catalyst update?

Phase 1

What is your next catalyst (value inflection) update?

Dec., 2025

Website

https://www.samjinpharm.co.kr/front/en/main/index.asp
Primary Speaker
Soo-Min Lee
Soo-Min Lee, PhD
CTO and Head of R&D
Samjin Pharmaceutical Co., Ltd.

BIO DOUBLE HELIX SPONSORS

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

BIO HELIX SPONSORS